Phase I/II trial of PAT-SM6 in combination with carfilzomib in patients with relapsed or refractory multiple myeloma
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2016
Price : $35 *
At a glance
- Drugs PAT SM6 (Primary) ; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Onyx Pharmaceuticals
- 13 Sep 2016 According to a Patrys media release, this trial continues to be on hold.
- 11 Jun 2015 According to Patrys media release, this trial is still on hold due to low manufacturing yield.
- 07 Nov 2014 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2015, according to a Patrys media release.